These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 33324150)

  • 1. Molecular Mechanisms of Glutamate Toxicity in Parkinson's Disease.
    Wang J; Wang F; Mai D; Qu S
    Front Neurosci; 2020; 14():585584. PubMed ID: 33324150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advance in the Relationship between Excitatory Amino Acid Transporters and Parkinson's Disease.
    Zhang Y; Tan F; Xu P; Qu S
    Neural Plast; 2016; 2016():8941327. PubMed ID: 26981287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms regulating spill-over of synaptic glutamate to extrasynaptic NMDA receptors in mouse substantia nigra dopaminergic neurons.
    Wild AR; Bollands M; Morris PG; Jones S
    Eur J Neurosci; 2015 Nov; 42(9):2633-43. PubMed ID: 26370007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells.
    Iovino L; Tremblay ME; Civiero L
    J Pharmacol Sci; 2020 Nov; 144(3):151-164. PubMed ID: 32807662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade.
    Schubert D; Piasecki D
    J Neurosci; 2001 Oct; 21(19):7455-62. PubMed ID: 11567035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons.
    Ballaz S; Morales I; Rodríguez M; Obeso JA
    J Neurosci Res; 2013 Dec; 91(12):1609-17. PubMed ID: 23996657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease.
    Plaitakis A; Shashidharan P
    J Neurol; 2000 Apr; 247 Suppl 2():II25-35. PubMed ID: 10991662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?
    Lewerenz J; Maher P
    Front Neurosci; 2015; 9():469. PubMed ID: 26733784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamate receptors in the substantia nigra of Parkinson's disease brains.
    Difazio MC; Hollingsworth Z; Young AB; Penney JB
    Neurology; 1992 Feb; 42(2):402-6. PubMed ID: 1346548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a Novel Mouse Model of Parkinson's Disease via Targeted Knockdown of Glutamate Transporter GLT-1 in the Substantia Nigra.
    Zhang Y; Meng X; Jiao Z; Liu Y; Zhang X; Qu S
    ACS Chem Neurosci; 2020 Feb; 11(3):406-417. PubMed ID: 31909584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mini-review of the role of vesicular glutamate transporters in Parkinson's disease.
    Zhao C; Wang C; Zhang H; Yan W
    Front Mol Neurosci; 2023; 16():1118078. PubMed ID: 37251642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate and Parkinson's disease.
    Blandini F; Porter RH; Greenamyre JT
    Mol Neurobiol; 1996 Feb; 12(1):73-94. PubMed ID: 8732541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra.
    Assous M; Had-Aissouni L; Gubellini P; Melon C; Nafia I; Salin P; Kerkerian-Le-Goff L; Kachidian P
    Neurobiol Dis; 2014 May; 65():69-81. PubMed ID: 24480091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of glutamate and excitotoxicity in neurologic diseases].
    Hugon J; Vallat JM; Dumas M
    Rev Neurol (Paris); 1996 Apr; 152(4):239-48. PubMed ID: 8763652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.
    Ambrosi G; Cerri S; Blandini F
    J Neural Transm (Vienna); 2014 Aug; 121(8):849-59. PubMed ID: 24380931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent elevation of D-Aspartate enhances NMDA receptor-mediated responses in mouse substantia nigra pars compacta dopamine neurons.
    Krashia P; Ledonne A; Nobili A; Cordella A; Errico F; Usiello A; D'Amelio M; Mercuri NB; Guatteo E; Carunchio I
    Neuropharmacology; 2016 Apr; 103():69-78. PubMed ID: 26707656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of glutamate transport and receptor binding by glutamate receptor antagonists in EAE rat brain.
    Sulkowski G; Dąbrowska-Bouta B; Salińska E; Strużyńska L
    PLoS One; 2014; 9(11):e113954. PubMed ID: 25426719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of ionotropic and metabotropic glutamate receptors in distinct neuronal elements of the rat substantia nigra.
    Yung KK
    Neurochem Int; 1998 Oct; 33(4):313-26. PubMed ID: 9840222
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.